Delivered his PhD thesis "Hypoxia in prostate cancer: Gene expression profiling in relation to disease aggressiveness and treatment interventions" in 2014.
Fernandez Salamanca M, van Houdt PJ, Hompland T, Deręgowska-Cylke M, van Leeuwen PJ, van der Poel HG, Bekers E, Guimaraes MAS, Lyng H, van der Heide UA, Schoots IG(2025) Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI BMC Med Imaging(in press) DOI 10.1186/s12880-025-02084-3, PubMed 41366753
Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K(2025) Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study Acta Oncol, 64, 439-447 DOI 10.2340/1651-226X.2025.43045, PubMed 40105683
Wang R, Gunesli GN, Skingen VE, Valen KF, Lyng H, Young LS, Rajpoot N(2025) Deep learning for predicting prognostic consensus molecular subtypes in cervical cancer from histology images NPJ Precis Oncol, 9(1), 11 DOI 10.1038/s41698-024-00778-5, PubMed 39799271
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@ous-hf.no
